Product Code: IRTNTR40128
About this market
Technavio's tumor (cancer) profiling market analysis considers sales from immunoassays, next-generation sequencing, polymerase chain reaction, and in-situ hybridization technologies. Our study also finds the sales of tumor (cancer) profiling in Asia, Europe, North America, and ROW. In 2019, the immunoassays segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as precise treatment decisions will play a significant role in the immunoassays segment to maintain its market position. Also, our global tumor (cancer) profiling market report looks at factors such as increasing incidences of cancer, low cost of genetic sequencing, and increasing awareness about tumor profiling. However, high cost of biomarkers development, lack of skilled professionals, and concerns related to variability in accuracy and precision in genomic analysis may hamper the growth of the tumor (cancer) profiling industry over the forecast period.
Overview
Increasing awareness about tumor profiling
Various government and private organizations and companies are creating awareness about the significance of tumor profiling, its diagnosis and personalized treatment of cancer. They are releasing educational videos and using email campaigns to educate both patients and physicians about the availability of effective and personalized treatment options and the need for genetic testing for timely diagnosis of cancer. Thus, increasing awareness about tumor profiling will lead to the expansion of the global tumor (cancer) profiling market at a CAGR of over 10% during the forecast period.
The growing importance of genomics in therapeutics
The importance of genomics technologies, such as microarray and genome editing in therapeutics, helped shape the future of therapeutics in pharmaceutical industries. Genomic profiling is done through polymerase chain reaction (PCR), ligase chain reaction (LCR), and transcription-mediated technologies. The rising focus of researchers on developing genomic databases, such as GenBank and the European Molecular Biology Laboratory (EMBL), has brought significant changes in the healthcare system by accelerating research progress in personalized medicines, drug development, clinical research, and gene therapies. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global tumor (cancer) profiling market during the forecast period 2020-2024, view our report.
Competitive Landscape
With the presence of several major players, the global tumor (cancer) profiling market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tumor (cancer) profiling manufacturers, that include Abbott Laboratories, Agilent Technologies Inc., Becton, Dickinson and Co., bioMerieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., QIAGEN NV, Siemens Healthineers AG, and Thermo Fisher Scientific Inc.
Also, the tumor (cancer) profiling market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
TABLE OF CONTENTS
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Value Chain Analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2019
- Market size and forecast 2019-2024
- Market Outlook
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TECHNOLOGY
- Market segmentation by technology
- Comparison by technology
- Immunoassays - Market size and forecast 2019-2024
- Next generation sequencing - Market size and forecast 2019-2024
- Polymerase chain reaction - Market size and forecast 2019-2024
- In-situ hybridization - Market size and forecast 2019-2024
- Market opportunity by technology
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Increasing cancer research and funding
- Increasing adoption of personalized medicine
- Growing importance of genomics in therapeutics
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Abbott Laboratories
- Agilent Technologies Inc.
- Becton, Dickinson and Co.
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- QIAGEN NV
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
PART 14: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
LIST OF EXHIBITS:
- Exhibit 01: Vendor: Key offerings
- Exhibit 02: Global healthcare technology market
- Exhibit 03: Segments of global healthcare technology market
- Exhibit 04: Market characteristics
- Exhibit 05: Market segments
- Exhibit 06: Market definition - Inclusions and exclusions checklist
- Exhibit 07: Market size 2019
- Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
- Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
- Exhibit 10: Five forces analysis 2019
- Exhibit 11: Five forces analysis 2024
- Exhibit 12: Bargaining power of buyers
- Exhibit 13: Bargaining power of suppliers
- Exhibit 14: Threat of new entrants
- Exhibit 15: Threat of substitutes
- Exhibit 16: Threat of rivalry
- Exhibit 17: Market condition - Five forces 2019
- Exhibit 18: Technology - Market share 2019-2024 (%)
- Exhibit 19: Comparison by technology
- Exhibit 20: Immunoassays - Market size and forecast 2019-2024 ($ millions)
- Exhibit 21: Immunoassays - Year-over-year growth 2020-2024 (%)
- Exhibit 22: Next generation sequencing - Market size and forecast 2019-2024 ($ millions)
- Exhibit 23: Next generation sequencing - Year-over-year growth 2020-2024 (%)
- Exhibit 24: Polymerase chain reaction - Market size and forecast 2019-2024 ($ millions)
- Exhibit 25: Polymerase chain reaction - Year-over-year growth 2020-2024 (%)
- Exhibit 26: In-situ hybridization - Market size and forecast 2019-2024 ($ millions)
- Exhibit 27: In-situ hybridization - Year-over-year growth 2020-2024 (%)
- Exhibit 28: Market opportunity by technology
- Exhibit 29: Customer landscape
- Exhibit 30: Market share by geography 2019-2024 (%)
- Exhibit 31: Geographic comparison
- Exhibit 32: North America - Market size and forecast 2019-2024 ($ millions)
- Exhibit 33: North America - Year-over-year growth 2020-2024 (%)
- Exhibit 34: Top 3 countries in North America
- Exhibit 35: Europe - Market size and forecast 2019-2024 ($ millions)
- Exhibit 36: Europe - Year-over-year growth 2020-2024 (%)
- Exhibit 37: Top 3 countries in Europe
- Exhibit 38: Asia - Market size and forecast 2019-2024 ($ millions)
- Exhibit 39: Asia - Year-over-year growth 2020-2024 (%)
- Exhibit 40: Top 3 countries in Asia
- Exhibit 41: ROW - Market size and forecast 2019-2024 ($ millions)
- Exhibit 42: ROW - Year-over-year growth 2020-2024 (%)
- Exhibit 43: Top 3 countries in ROW
- Exhibit 44: Key leading countries
- Exhibit 45: Market opportunity
- Exhibit 46: Impact of drivers and challenges
- Exhibit 47: Vendor landscape
- Exhibit 48: Landscape disruption
- Exhibit 49: Vendors covered
- Exhibit 50: Vendor classification
- Exhibit 51: Market positioning of vendors
- Exhibit 52: Abbott Laboratories - Vendor overview
- Exhibit 53: Abbott Laboratories - Business segments
- Exhibit 54: Abbott Laboratories - Organizational developments
- Exhibit 55: Abbott Laboratories - Geographic focus
- Exhibit 56: Abbott Laboratories - Segment focus
- Exhibit 57: Abbott Laboratories - Key offerings
- Exhibit 58: Abbott Laboratories - Key customers
- Exhibit 59: Agilent Technologies Inc. - Vendor overview
- Exhibit 60: Agilent Technologies Inc. - Product segments
- Exhibit 61: Agilent Technologies Inc. - Organizational developments
- Exhibit 62: Agilent Technologies Inc. - Geographic focus
- Exhibit 63: Agilent Technologies Inc. - Segment focus
- Exhibit 64: Agilent Technologies Inc. - Key offerings
- Exhibit 65: Agilent Technologies Inc. - Key customers
- Exhibit 66: Becton, Dickinson and Co. - Vendor overview
- Exhibit 67: Becton, Dickinson and Co. - Business segments
- Exhibit 68: Becton, Dickinson and Co. - Organizational developments
- Exhibit 69: Becton, Dickinson and Co. - Geographic focus
- Exhibit 70: Becton, Dickinson and Co. - Segment focus
- Exhibit 71: Becton, Dickinson and Co. - Key offerings
- Exhibit 72: Becton, Dickinson and Co. - Key customers
- Exhibit 73: bioMerieux SA - Vendor overview
- Exhibit 74: bioMerieux SA - Product segments
- Exhibit 75: bioMerieux SA - Organizational developments
- Exhibit 76: bioMerieux SA - Geographic focus
- Exhibit 77: bioMerieux SA - Key offerings
- Exhibit 78: bioMerieux SA - Key customers
- Exhibit 79: Bio-Rad Laboratories Inc. - Vendor overview
- Exhibit 80: Bio-Rad Laboratories Inc. - Business segments
- Exhibit 81: Bio-Rad Laboratories Inc. - Organizational developments
- Exhibit 82: Bio-Rad Laboratories Inc. - Geographic focus
- Exhibit 83: Bio-Rad Laboratories Inc. - Segment focus
- Exhibit 84: Bio-Rad Laboratories Inc. - Key offerings
- Exhibit 85: Bio-Rad Laboratories Inc. - Key customers
- Exhibit 86: F. Hoffmann-La Roche Ltd. - Vendor overview
- Exhibit 87: F. Hoffmann-La Roche Ltd. - Business segments
- Exhibit 88: F. Hoffmann-La Roche Ltd. - Organizational developments
- Exhibit 89: F. Hoffmann-La Roche Ltd. - Geographic focus
- Exhibit 90: F. Hoffmann-La Roche Ltd. - Segment focus
- Exhibit 91: F. Hoffmann-La Roche Ltd. - Key offerings
- Exhibit 92: F. Hoffmann-La Roche Ltd. - Key customers
- Exhibit 93: Illumina Inc. - Vendor overview
- Exhibit 94: Illumina Inc. - Business segments
- Exhibit 95: Illumina Inc. - Organizational developments
- Exhibit 96: Illumina Inc. - Geographic focus
- Exhibit 97: Illumina Inc. - Segment focus
- Exhibit 98: Illumina Inc. - Key offerings
- Exhibit 99: Illumina Inc. - Key customers
- Exhibit 100: QIAGEN NV - Vendor overview
- Exhibit 101: QIAGEN NV - Product segments
- Exhibit 102: QIAGEN NV - Organizational developments
- Exhibit 103: QIAGEN NV - Geographic focus
- Exhibit 104: QIAGEN NV - Segment focus
- Exhibit 105: QIAGEN NV - Key offerings
- Exhibit 106: QIAGEN NV - Key customers
- Exhibit 107: Siemens Healthineers AG - Vendor overview
- Exhibit 108: Siemens Healthineers AG - Business segments
- Exhibit 109: Siemens Healthineers AG - Organizational developments
- Exhibit 110: Siemens Healthineers AG - Geographic focus
- Exhibit 111: Siemens Healthineers AG - Segment focus
- Exhibit 112: Siemens Healthineers AG - Key offerings
- Exhibit 113: Siemens Healthineers AG - Key customers
- Exhibit 114: Thermo Fisher Scientific Inc. - Vendor overview
- Exhibit 115: Thermo Fisher Scientific Inc. - Business segments
- Exhibit 116: Thermo Fisher Scientific Inc. - Organizational developments
- Exhibit 117: Thermo Fisher Scientific Inc. - Geographic focus
- Exhibit 118: Thermo Fisher Scientific Inc. - Segment focus
- Exhibit 119: Thermo Fisher Scientific Inc. - Key offerings
- Exhibit 120: Thermo Fisher Scientific Inc. - Key customers
- Exhibit 121: Validation techniques employed for market sizing
- Exhibit 122: Definition of market positioning of vendors
